In vitro, TGF-β inhibits the expression of NKp30 and NKG2D (37) and blood concentration of TGF-β1 was shown to inversely correlate with NKG2D expression at the surface of NK cells of cancer patients and has been linked with impaired NK cytotoxicity (58, 60). The gene discussed is NCR3; the disease is cancer.